Urogen Pharma Ltd
NASDAQ:URGN
Urogen Pharma Ltd
Research & Development
Urogen Pharma Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Research & Development
-$67.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Research & Development
-$12.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Research & Development
-$9.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Research & Development
-$5.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Research & Development
-$15.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Research & Development
-₪10.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Urogen Pharma Ltd
Glance View
UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
See Also
What is Urogen Pharma Ltd's Research & Development?
Research & Development
-67.1m
USD
Based on the financial report for Dec 31, 2025, Urogen Pharma Ltd's Research & Development amounts to -67.1m USD.
What is Urogen Pharma Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-7%
Over the last year, the Research & Development growth was -17%. The average annual Research & Development growth rates for Urogen Pharma Ltd have been -8% over the past three years , -7% over the past five years .
